Kalaris Therapeutics, Inc. (KLRS)
Listed in the US · Manufacturing · Biological products, (no diagnostic substances)
$2.13
As of 29 Oct 2026 close.
Facts from reported results and exchange filings. Not investment advice.
Share price
Prices load here as you scroll to them.
Last close $2.13 on 29 Oct 2026. The share price traded between $1.78 and $11.88 (intraday) over the last 12 months.
The closes as a table
| Date | Close |
|---|
Key figures
1-year range (intraday)
Low $1.78High $11.88
Price trend
- Stage 4 (declining): the price is below a falling 150-day average, for 87 trading days.
- Supertrend (10, 3): the price has closed below the line for 157 trading days.
Revenue and profit
| Year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Net profit | -172 | -169 | -190 | -69 | -43 |
$ million.
Recent filings
- 11 Aug 2026
Quarterly report (10-Q) - 11 Aug 2026
Earnings release (8-K) - 12 May 2026
Quarterly report (10-Q) - 12 May 2026
Earnings release (8-K) - 17 Mar 2026
Annual report (10-K) - 17 Mar 2026
Earnings release (8-K)
Questions about Kalaris Therapeutics, Inc.
What is Kalaris Therapeutics, Inc.'s market value?
Kalaris Therapeutics, Inc.'s market value is $51M as of 29 Oct 2026 close: the last close times the shares in issue.
Go further with KLRS
Free to start: test a trading idea on KLRS's real prices after costs, or open the full deep dive with ten years of numbers, red flags and management's record.
Same industry
The largest companies in the same industry (Biological products, (no diagnostic substances)), by market value.
Browse companies
The companies before and after this one, A to Z, and the lists it is in.
How these figures are worked out
- Last close: the closing price on the date shown. The page follows the market's close; it doesn't show prices during the session. A price older than the market's latest close, or a last trade that isn't a close, is labelled as the last price, with the session it is from.
- 1-year range: the lowest and highest prices traded during the sessions of the last year (intraday), so they can lie outside the closing prices.
- Market cap: the last close times the shares in issue. It is n/a when it doesn't agree with the company's own reported figures (for example a depositary share counted as an ordinary share).
- P/E: the last close divided by earnings per share over the last four reported quarters, the profit that belongs to the company's shareholders per share, as the company reports it. So P/E can differ from market cap divided by the net profit shown (a different share count, or the profit before minority interests; where they differ by more than 10%, a note under the figures gives both). A company that reports only once a year has its latest year's earnings, and the P/E names that year; when that year ended more than about 15 months before the close, P/E is n/a. A loss has no P/E. Above 1,000 it is n/a.
- EBITDA margin: operating profit before depreciation, interest and tax (and before other income), as a share of revenue in the latest reported year, the table's last column.
- Net margin: net profit as a share of revenue in the latest reported period. Return on equity, the margins and debt to equity each use inputs from that one year; if one input is missing for it, the figure is n/a. When that year ended more than about 15 months before the close, they are n/a too.
- Dividend yield: every dividend per share with an ex-date in the 12 months to the last close, special dividends included, as a share of that close. n/a when the company's dividends couldn't be read.
- n/m: not meaningful. A margin or return beyond ±1,000% comes from revenue or equity near zero, so it is not shown as a number.